WASHINGTON — Treatment with vupanorsen, a novel antisense oligonucleotide targeting hepatic ANGPTL3, achieved modest reductions in non-HDL at 24 weeks at all doses studied, according to results of the TRANSLATE-TIMI 70 trial.
Patients assigned vupanorsen at higher doses had increased rates of injection-site reactions, elevations in liver enzymes and dose-related increases in hepatic fat accumulation, researchers reported at the American College of Cardiology Scientific Session.
The TRANSLATE-TIMI 70 trial evaluated the effects of escalating doses of vupanorsen (Ionis) on non-HDL in adults